Everything below concerns peptide backbone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-27. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
AHCC is widely used in the world and many people use it for general health maintenance and treatment of various diseases. It is often used as a complementary and alternative medicine (CAM) for immune support, as reports in animal and clinical settings have indicated that AHCC is associated with an enhanced response to infection and increased survival. AHCC is in some cases also used by those undergoing conventional cancer therapy (e.g. chemotherapy) for its reported immunomodulatory functions. In Japan, AHCC is the 2nd most popular complementary and alternative medicine used by cancer patients. Agaricus blazei supplements are the most popular, outpacing AHCC use by a factor of 7:1.
ADAM17 is an 824-amino acid polypeptide. ADAM17 has multidomain structure that includes a pro-domain, a metallo-protease domain, a disintegrin domain, a cysteine-rich domain, an EGF-like domain, a transmembrane domain, and a cytoplasmic tail. The metalloprotease domain is responsible for the enzyme's catalytic activity, cleaving membrane-bound proteins, including cytokines like TNF-alpha, to release their soluble forms. The disintegrin and cysteine-rich domains are implicated in cell adhesion and interaction with integrins, while the transmembrane domain anchors the protein in the membrane. The cytoplasmic tail is involved in intracellular signaling and protein-protein interactions. ADAM17's activity is tightly regulated through multiple mechanisms, including the removal of its pro-domain and interactions with regulatory proteins such as TIMPs (tissue inhibitors of metalloproteinases).
The bioanalyst deals with complex biological samples containing the analyte alongside a diverse range of chemicals that can have an adverse impact on the accurate and precise quantification of the analyte. As such, a wide range of techniques are applied to extract the analyte from its matrix. These include: Protein precipitation Liquid–liquid extraction Solid phase extraction Bioanalytical laboratories often deal with large numbers of samples, for example resulting from clinical trials. As such, automated sample preparation methods and liquid-handling robots are commonly employed to increase efficiency and reduce costs.
The H-type pseudoknot core of mini-NAD⁺-II aptamers is structurally analogous to that of the preQ1-I riboswitch class, one of the smallest known natural riboswitch aptamers. Both classes represent the shortest known natural RNA aptamers, yet achieve high ligand-binding specificity. This structural similarity suggests that simple H-type pseudoknots may function as versatile scaffolds for constructing ligand-binding aptamers, either naturally or synthetically. Biochemical analysis using in-line probing confirmed that mini-NAD⁺-II RNAs bind both NAD⁺ and NMN, with strong preference for NMN. Biochemical analysis using in-line probing confirmed that mini-NAD⁺-II RNAs bind both NAD⁺ and NMN, with strong preference for NMN. Mini-NAD⁺-II aptamers discriminate more strongly between NMN and NAD⁺ than the larger P1a containing aptamers, likely because they lack the conserved adenosines flanking P1a that make non-specific contacts with the adenosine moiety of NAD⁺. Gene Regulation NAD⁺-II and mini-NAD⁺-II riboswitches are predicted to function as translational "OFF" switches: when NAD⁺ or NMN concentrations are sufficiently high, the riboswitch ligand-bound conformation sequesters the Shine-Dalgarno sequence within a pseudoknot, preventing ribosome binding and repressing translation of the downstream gene. The downstream genes regulated by NAD⁺-II and mini-NAD⁺-II riboswitches include:
Sources: en.wikipedia.org
BLAST is an algorithm for comparing biomacromolecule primary structure, most often nucleotide sequence of DNA/RN, and amino acid sequence of proteins, stored in the bioinformatic databases, with the query sequence. The algorithm uses scoring of the available sequences against the query by a scoring matrix such as BLOSUM 62. The highest scoring sequences represent the closest relatives of the query, in terms of functional and evolutionary similarity. The database search by BLAST requires input data to be in a correct format (e.g. FASTA, GenBank, PIR or EMBL format). Users may also designate the specific databases to be searched, select scoring matrices to be used and other parameters prior to the tool run. The best hits in the BLAST results are ordered according to their calculated E-value (the probability of the presence of a similarly or higher-scoring hit in the database by chance).
Adrenomedullin (ADM) is a peptide hormone that plays an important role in various physiological processes throughout the human body. Initially discovered in 1993 from a pheochromocytoma, a tumor of the adrenal medulla, this 52-amino acid peptide is now recognized for its diverse effects, including vasodilation, regulation of blood pressure, and maintenance of the vascular system. ADM is widely expressed in tissues and also found in the circulation, exerting its influence on the cardiovascular, lymphatic, and endocrine systems, as well as demonstrating anti-inflammatory and tissue-protective properties. In humans, ADM is encoded by the ADM gene. A similar peptide named adreomedullin2 was reported in rats in 2004, which exhibits a similar function.
This protein is known to interact with multiple human proteins, verified via two-hybrid screening. A few notable examples include: LATS2: Negatively regulates YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting cell proliferation and promoting apoptosis. ZGPAT (Zinc finger CCCH-type with G patch domain-containing protein): A transcription repressor that negatively regulates expression of EGFR, a gene involved in cell proliferation, survival and migration, suggesting that it may act as a tumor suppressor. RCOR3 (REST Corepressor 3): A protein that may act as a component of a co-repressor complex that represses transcription It also interacts with viral proteins such as: Replicase polyprotein 1ab (SARS-CoV2): A multifunctional protein involved in the transcription and replication of viral RNAs. Protein E7 (Human Papillomavirus): Plays a role in viral genome replication by driving entry of quiescent cells into the cell cycle.
Femarelle is a dietary supplement range containing DT56a, a tofu-derived soy extract, together with additional ingredients including flaxseed powder, vitamins, and minerals. DT56a has been studied for its potential activity as a selective estrogen receptor modulator (SERM), meaning that it may interact selectively with estrogen receptors in different tissues. Femarelle has been evaluated in several clinical studies investigating its possible role in supporting women during menopause, including studies on menopausal symptoms, vaginal health, bone health, and safety profile. Some studies reported encouraging findings, including improvements in menopausal symptoms and a favorable safety profile compared with traditional hormone replacement therapy, although the published trials were generally limited by relatively small sample sizes and short study durations. In 2008, an application was submitted to the European Food Safety Authority (EFSA) regarding a health claim related to bone mineral density and osteoporosis risk. EFSA concluded that the available evidence at that time was insufficient to establish a cause-and-effect relationship between Femarelle consumption and improvements in bone mineral density or reduction of osteoporosis risk in postmenopausal women.
Antibody diversity is produced by genetic rearrangement after shuffling and rejoining one of each of the various gene segments for the heavy and light chains. Due to mixing and random recombination of the gene segments errors can occur at the sites where gene segments join with each other. These errors are one of the sources of the antibody diversity that is commonly observed in both the light and heavy chains. Moreover, when B cells continue to proliferate, mutations accumulate at the variable regions through a process called somatic hypermutation. The high concentrations of these mutations at the variable region also produce high antibody diversity.
Sources: en.wikipedia.org
Post-crash survivability is the chance that drivers and passengers survive a crash after it occurs. Technology such as Advanced Automatic Collision Notification can automatically place calls to emergency services and send information about a vehicle collision. Cars are much more dangerous to pedestrians than they are to drivers and passengers. Two-thirds of 1.3 million yearly auto related deaths are pedestrians. Since at least the early 1970s, attention has also been given to vehicle design regarding the safety of pedestrians in car-pedestrian collisions. Proposals in Europe would require cars sold there to have a minimum/maximum hood (bonnet) height. From 2006, the use of "bull bars", a fashion on 4x4s and SUVs, became illegal in the European Union, after having been banned on all new cars in 2002. Recent research has explored the use of multimodal sensor fusion to improve pedestrian detection in challenging conditions, including low-light environments and unusual pedestrian postures such as prone or fallen individuals.
Stanford dedicated the BIL gate's design to the public domain, which may speed its adoption. According to Endy, other researchers were already using the gates to reprogram metabolism when the Stanford team published its research. Computing by transcriptor is still very slow; it can take a few hours between receiving an input signal and generating an output. Endy doubted that biocomputers would ever be as fast as traditional computers, but added that is not the goal of his research. "We're building computers that will operate in a place where your cellphone isn't going to work", he said. Medical devices with built-in biological computers could monitor, or even alter, cell behavior from inside a patient's body. ExtremeTech writes:
Although PI3K is the major mode of Akt activation, other tyrosine or serine/threonine kinases have been shown to activate Akt directly, in response to growth factors, inflammation or DNA damage. These can function even when PI3K activity is inhibited. Other studies have shown Akt can be activated in response to heat shock or increases in cellular Ca2+ concentration, via Ca2+/Calmodulin-dependent protein kinase kinase (CAMKK).
The GRP RNA motif is a conserved RNA structural element identified in introns of glycine-rich RNA-binding protein genes, including GRP7 and GRP8. It is associated with alternative splicing and nonsense-mediated decay (NMD). GRP RNA motif has been reported as a cis-regulatory element, that modulates binding of GRP7 and GRP8 proteins to their RNA targets. The motif is predicted to form a stem-loop structure of approximately 20 base pairs. An alternative 5′ splice site is located near the base of the stem, suggesting that RNA structure may influence splice-site accessibility. In Arabidopsis thaliana (At), AtGRP7 and AtGRP8 are circadian clock-regulated RNA-binding proteins that form an interlocked auto-regulatory and cross-regulatory feedback network based on alternative splicing and NMD of their own pre-mRNAs, contributing to circadian output regulation, were transcript levels oscillate with a daily rhythm. GRP7 and GRP8 are also involved in regulating flowering time. Homologous motifs of GRP RNA motif have been identified in multiple plant species within the Pentapetalae clade.
Pyocyanin (PCN−) is one of the many toxic compounds produced and secreted by the Gram negative bacterium Pseudomonas aeruginosa. Pyocyanin is a blue secondary metabolite, turning red below pH 4.9, with the ability to oxidise and reduce other molecules and therefore kill microbes competing against P. aeruginosa as well as mammalian cells of the lungs which P. aeruginosa has infected during cystic fibrosis. Since pyocyanin is a zwitterion at blood pH, it is easily able to cross the cell membrane. There are three different states in which pyocyanin can exist: oxidized (blue), monovalently reduced (colourless) or divalently reduced (red). Mitochondria play an important role in the cycling of pyocyanin between its redox states. Due to its redox-active properties, pyocyanin generates reactive oxygen species.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。